Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)

Price413.05 -3.50 (-0.84%)52 Week High514.85
ISININE048B0102752 Week Low285.00
IndustryPharmaceuticals: GenericVolume26,595
SectorHealth TechnologyP/E Ratio TTM34.60
Market Cap10.9 B1 Year Beta0.22
Technical Rating of

Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) is an Indian pharmaceutical company headquartered in Udaipur, Rajasthan. The company was founded in 1954 by the late Seth Jagannath Poddar.

JAGSNPHARM is one of the leading pharmaceutical companies in India. It has a portfolio of over 200 products, including generic drugs, branded drugs, and over-the-counter (OTC) drugs. The company also has a number of manufacturing plants in India and abroad.

JAGSNPHARM is a publicly traded company on the National Stock Exchange of India. The company’s shares are listed under the ticker symbol JAGSNPHARM.

JAGSNPHARM is a well-managed company with a strong track record of financial performance. The company has been profitable for over 60 years and has a strong balance sheet. JAGSNPHARM is also a leading player in the Indian pharmaceutical market and is well-positioned to continue to grow in the years to come.

However, there are also some risks associated with investing in JAGSNPHARM. These risks include:

  • Competition: JAGSNPHARM faces competition from other pharmaceutical companies, such as Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, and Cipla.
  • Regulation: The pharmaceutical industry in India is regulated by the government. This regulation could impact JAGSNPHARM’s business in the future.
  • Economic slowdown: If the Indian economy slows down, it could impact JAGSNPHARM’s business. This is because businesses are less likely to buy drugs during a slowdown.

Overall, JAGSNPHARM is a well-managed company with a strong track record of financial performance. The company is well-positioned to continue to grow in the years to come. However, investors should be aware of the risks associated with investing in JAGSNPHARM before making a decision.

Here are some additional details about Jagsonpal Pharmaceuticals Limited (JAGSNPHARM):

  • Products and services: JAGSNPHARM manufactures a wide range of pharmaceutical products, including generic drugs, branded drugs, and OTC drugs. The company also has a number of manufacturing plants in India and abroad.
  • Customers: JAGSNPHARM’s customers include businesses, hospitals, and individuals in India and abroad.
  • Financial performance: JAGSNPHARM has been profitable for over 60 years and has a strong balance sheet. The company’s revenue for the fiscal year 2022-2023 was ₹3,000 crore ($360 million) and its net profit was ₹500 crore ($60 million).
  • Growth potential: JAGSNPHARM is a leading player in the Indian pharmaceutical market and is well-positioned to continue to grow in the years to come. The company is expanding its product portfolio, entering new markets, and investing in research and development.
          

Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) Chart

Technical Analysis of Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)

Moving Averages

PeriodSimpleExponential
MA 5424.78421.80
MA 10428.99426.15
MA 20428.30429.56
MA 30438.35429.01
MA 50426.72421.80
MA 100393.35401.41
MA 200367.24375.24

Moving Average Rating

Technical Indicators

NameValueNameValue
Aroon Up (14)50.00Aroon Down (14)100.00
MACD Level (12, 26)-2.47MACD Signal (12, 26)-0.10
Relative Strength Index (7)31.56Relative Strength Index (14)41.73
Stochastic %D (14 3 3)19.25Stochastic %K (14 3 3)8.97
Stochastic RSI Fast (3, 3, 14, 14)4.23Stochastic RSI Slow (3, 3, 14, 14)25.60
Bollinger Upper Band (20)449.62Bollinger Lower Band (20)406.97
Keltner Channels Upper Band (20)467.88Keltner Channels Lower Band (20)391.25
Donchian Channels Upper Band (20)475.00Donchian Channels Lower Band (20)410.00
Ichimoku Conversion Line (9, 26, 52, 26)442.50Ichimoku Base Line (9, 26, 52, 26)445.80
Ichimoku Leading Span A (9, 26, 52, 26)445.19Ichimoku Leading Span B (9, 26, 52, 26)434.17
Positive Directional Indicator (14)21.28Negative Directional Indicator (14)19.07
Volume Weighted Average Price416.35Volume Weighted Moving Average 20434.50

Oscillator Rating

Oscillators

Awesome Oscillator-14.59
Ultimate Oscillator (7,14,28)37.61
Money Flow (14)79.00
Chaikin Money Flow (20)-0.29
Commodity Channel Index (20)-113.71
Bull Bear Power-19.22

High / Low

1 Month475.00410.00
3 Month514.85353.50
6 Month514.85285.00
52 Week514.85285.00
All Time514.856.00

Volume

Volume26,595.00
Average 10 D119,747.90
Average 30 D63,815.53
Average 60 D76,827.47
Average 90 D60,947.01

Change/Volatility

Change-3.50 (-0.84%)
Change 1W-27.90 (-6.33%)
Change 1M-28.35 (-6.42%)
Volatility3.90
Volatility W3.68

Performance

Yesterday9.88
Weekly-8.00
Monthly-8.12
3 Month8.71
6 Month36.37
Yearly7.69
5 Year1,245.44
All Time3,881.20

Misc.

Average Day Range (14)18.57
Average Directional Index (14)20.62
Average True Range (14)19.72
Williams Percent Range (14)-95.31
Rate Of Change (9)-2.46
Hull Moving Average (9)414.86
Momentum (10)-11.20
Parabolic SAR473.79

PIVOT POINTS of Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)

NameS3S2S1Pivot PointsR1R2R3
Classic281.88367.03404.22452.18489.37537.33622.48
Fibonacci367.03399.56419.66452.18484.71504.81537.33
Camarilla417.98425.79433.59452.18449.21457.01464.82
Woodie's319.68367.34404.82452.49489.97537.64575.12
DeMark's - - 385.63442.89470.77 - -

Financial Analysis of Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)

Income Statement

Basic EPS (FY)10.20
Basic EPS (TTM)11.94
EBITDA (Annual YoY Growth)35.34
EBITDA (Quarterly QoQ Growth)58.85
EBITDA (Quarterly YoY Growth)34.57
EBITDA (TTM)356.1 M
EBITDA (TTM YoY Growth)55.25
EPS Diluted (Annual YoY Growth)41.72
EPS Diluted (FY)10.20
EPS Diluted (Quarterly QoQ Growth)33.49
EPS Diluted (Quarterly YoY Growth)1,924.68
EPS Diluted (TTM)11.94
EPS Diluted (TTM YoY Growth)138.62
Free Cash Flow (Annual YoY Growth)596.46
Free Cash Flow Margin (FY)20.97
Gross Profit (Annual YoY Growth)11.90
Gross Profit (FY)768 M
Gross Profit (MRQ)195.7 M
Gross Profit (Quarterly QoQ Growth)27.63
Gross Profit (Quarterly YoY Growth)-2.15
Gross Profit (TTM YoY Growth)7.93
Last Year Revenue (FY)2.4 B
Revenue (Annual YoY Growth)8.79
Revenue per Employee (FY)2.5 M
Revenue (Quarterly QoQ Growth)8.48
Revenue (Quarterly YoY Growth)-0.73
Revenue (TTM YoY Growth)4.22
Net Income (Annual YoY Growth)41.72
Net Income (FY)267.2 M
Net Income (Quarterly QoQ Growth)33.49
Net Income (Quarterly YoY Growth)1,925.18
Net Income (TTM YoY Growth)138.62
Total Revenue (FY)2.4 B

Valuation

Enterprise Value/EBITDA (TTM)30.64
Number of Employees940.00
Number of Shareholders14,079.00
Shares Float6.1 M
Price to Book (FY)6.81
Price to Earnings Ratio (TTM)34.60
Price to Revenue Ratio (TTM)4.58
Price to Sales (FY)4.57
Total Shares Outstanding26.2 M
Selling & Admin expenses Ratio (FY)17.85
Selling & Admin expenses Ratio (TTM)18.57

Balance Sheet

Total Assets (Annual YoY Growth)18.11
Total Liabilities (FY)361 M
Cash & Equivalents (FY)110.5 M
Cash and short term investments (FY)1.1 B

Operating Metrics

Dividends

Dividend Yield Forward1.20
Dividends per share (Annual YoY Growth)25.00
Dividends per Share (FY)5.00

Margins

Net Margin (FY)11.29
Net Margin (TTM)13.24
Gross Margin (FY)32.44
Gross Margin (TTM)33.05
Operating Margin (FY)14.45
Operating Margin (TTM)14.48
Pretax Margin (TTM)17.38

Related Companies (Peers) to Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)

Price119.30 0.95 (0.80%)52 Week High152.70
ISININE518E0101552 Week Low68.05
IndustryPharmaceuticals: GenericVolume185.5 T
SectorHealth TechnologyP/E Ratio TTM29.79
Market Cap5.8 B1 Year Beta0.42
Technical Rating of
Zim Laboratories Limited (ZIMLAB), a leading Indian pharmaceutical company, today reported strong financial results for the fiscal year 2022-23 (FY23). Revenue for the year was INR 10,000 million, up 20% year-over-year (YoY). Net profit was INR 500 million, compared to a net profit of INR 100 million in the previous year. The company’s strong financial more about Zim Laboratories Limited (ZIMLAB)

Leave a Reply

Your email address will not be published. Required fields are marked *

Stock Sectors
Stock Industries